Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21944586 | 1.00 | HRH3 (0.33) | HRH3PIK3CDTSHRSMN1; SMN2FDPS | |
| SCHEMBL20462783 | 0.87 | FDPS (0.36) | HRH3FDPSCA2ALOX5 | |
| SCHEMBL12685243 | 0.84 | KDM4E (0.37) | HRH3PIK3CDCA2LMNACA12 | |
| SCHEMBL8108356 | 0.83 | USP2 (0.36) | HRH3USP2 | |
| SCHEMBL20143293 | 0.78 | HRH3 (0.40) | HRH3TSHRSMN1; SMN2FDPSMAPK1 | |
| SCHEMBL5948779 | 0.78 | HRH3 (0.40) | HRH3TSHRSMN1; SMN2FDPSMAPK1 | |
| SCHEMBL12698815 | 0.76 | HRH3 (0.42) | HRH3TSHRSMN1; SMN2FDPSMAPK1 | |
| SCHEMBL26767784 | 0.76 | HRH3 (0.42) | HRH3TSHRSMN1; SMN2FDPSMAPK1 | |
| SCHEMBL3585010 | 0.75 | MC4R (0.41) | TSHRSMN1; SMN2FDPSCA2CA1 | |
| SCHEMBL3585361 | 0.75 | MC4R (0.41) | TSHRSMN1; SMN2FDPSCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557117-B2 | 4-oxoimidazolidine-2-spiropiperidine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-07 | — | — | US | disclosed |
| EP-1420020-B1 | 4-OXOIMIDAZOLIDINE-2-SPIROPIPERIDINE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20070078153-A1 | 4-Oxoimidazolidine-2-spiropiperidine derivatives | MSD K.K. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-7192964-B2 | 4-oxoimidazolidine-2-spiropiperidine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20050004363-A1 | 4-oxoimidazolidine-2-spiropiperidine derivatives | MSD K.K. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1420020-A1 | 4-OXOIMIDAZOLIDINE-2-SPIROPIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078153-A1 | 4-Oxoimidazolidine-2-spiropiperidine derivatives | OPRL1, OPRK1, OPRD1 | HRH3 643/4885PIK3CD 4693/4885TSHR 77/4885 |
| US-20050004363-A1 | 4-oxoimidazolidine-2-spiropiperidine derivatives | OPRL1, OPRD1, OPRK1 | HRH3 685/4885PIK3CD 4641/4885TSHR 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.